These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 17845140)
1. The continuing complexities of high-density lipoprotein metabolism in drug discovery and development. Suckling K Expert Opin Ther Targets; 2007 Sep; 11(9):1133-6. PubMed ID: 17845140 [TBL] [Abstract][Full Text] [Related]
3. New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib. Pérez-Castrillon JL; Dueñas-Laita A Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):109-14. PubMed ID: 18221079 [TBL] [Abstract][Full Text] [Related]
4. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Barter P Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939 [TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469 [TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Shinkai H Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630 [TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466 [TBL] [Abstract][Full Text] [Related]
9. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development. Zhao L; Jin W; Rader D; Packard C; Feuerstein G Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799 [TBL] [Abstract][Full Text] [Related]
10. Is raising HDL a futile strategy for atheroprotection? Joy T; Hegele RA Nat Rev Drug Discov; 2008 Feb; 7(2):143-55. PubMed ID: 18239670 [TBL] [Abstract][Full Text] [Related]
11. Effect of torcetrapib on the progression of coronary atherosclerosis. Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM; N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129 [TBL] [Abstract][Full Text] [Related]
12. JTT-705: is there still future for a CETP inhibitor after torcetrapib? Rennings AJ; Stalenhoef A Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319 [TBL] [Abstract][Full Text] [Related]
13. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Clark RW Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747 [TBL] [Abstract][Full Text] [Related]
14. The role of CETP inhibition in dyslipidemia. El Harchaoui K; van der Steeg WA; Stroes ES; Kastelein JJ Curr Atheroscler Rep; 2007 Aug; 9(2):125-33. PubMed ID: 17877921 [TBL] [Abstract][Full Text] [Related]
15. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
17. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. Williams SA; Murthy AC; DeLisle RK; Hyde C; Malarstig A; Ostroff R; Weiss SJ; Segal MR; Ganz P Circulation; 2018 Mar; 137(10):999-1010. PubMed ID: 28974520 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. Davidson MH; McKenney JM; Shear CL; Revkin JH J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249 [TBL] [Abstract][Full Text] [Related]
19. Effects of torcetrapib in patients at high risk for coronary events. Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B; N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165 [TBL] [Abstract][Full Text] [Related]